C
West Pharmaceutical Services, Inc.
WST
$331.73
-$5.18-1.54%
C
Hold
1/8/2025Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 1/8/2025 due to an increase in the volatility index and total return index.
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 1/8/2025 due to an increase in the volatility index and total return index.
C
Hold
12/23/2024Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 12/23/2024 due to a decline in the volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 12/23/2024 due to a decline in the volatility index and valuation index.
C
Hold
12/6/2024Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 12/6/2024 due to an increase in the total return index.
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 12/6/2024 due to an increase in the total return index.
C
Hold
11/12/2024Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 11/12/2024 due to a decline in the valuation index, efficiency index and volatility index.
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 11/12/2024 due to a decline in the valuation index, efficiency index and volatility index.
C
Hold
10/25/2024Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 10/25/2024 due to an increase in the volatility index and solvency index. The quick ratio increased from 1.5 to 2.05, and debt to equity declined from 0.09 to 0.08.
West Pharmaceutical Services, Inc. (WST) was upgraded to C from C- on 10/25/2024 due to an increase in the volatility index and solvency index. The quick ratio increased from 1.5 to 2.05, and debt to equity declined from 0.09 to 0.08.
C
Hold
10/15/2024Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 10/15/2024 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from $1.55 to $1.51.
West Pharmaceutical Services, Inc. (WST) was downgraded to C- from C on 10/15/2024 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from $1.55 to $1.51.
C
Hold
4/26/2024Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 4/26/2024 due to a noticeable decline in the growth index, solvency index and valuation index. Operating cash flow declined 50.56% from $239.1M to $118.2M, EBIT declined 27.4% from $173M to $125.6M, and earnings per share declined from $1.8212 to $1.55.
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 4/26/2024 due to a noticeable decline in the growth index, solvency index and valuation index. Operating cash flow declined 50.56% from $239.1M to $118.2M, EBIT declined 27.4% from $173M to $125.6M, and earnings per share declined from $1.8212 to $1.55.
C
Hold
3/11/2024Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 3/11/2024 due to an increase in the total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 3/11/2024 due to an increase in the total return index and valuation index.
C
Hold
11/16/2023Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 11/16/2023 due to a decline in the total return index, growth index and efficiency index.
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 11/16/2023 due to a decline in the total return index, growth index and efficiency index.
C
Hold
10/30/2023Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 10/30/2023 due to an increase in the valuation index, solvency index and efficiency index. Net income increased 4% from $155.1M to $161.3M, total capital increased 3.83% from $3.06B to $3.18B, and the quick ratio increased from 2.64 to 2.69.
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 10/30/2023 due to an increase in the valuation index, solvency index and efficiency index. Net income increased 4% from $155.1M to $161.3M, total capital increased 3.83% from $3.06B to $3.18B, and the quick ratio increased from 2.64 to 2.69.
C
Hold
10/20/2023Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 10/20/2023 due to a noticeable decline in the valuation index and solvency index. The quick ratio declined from 2.65 to 2.64.
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 10/20/2023 due to a noticeable decline in the valuation index and solvency index. The quick ratio declined from 2.65 to 2.64.
C
Hold
3/29/2023Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 3/29/2023 due to an increase in the total return index and solvency index. Debt to equity declined from 0.09 to 0.08, and the quick ratio increased from 2.7 to 2.73.
West Pharmaceutical Services, Inc. (WST) was upgraded to C+ from C on 3/29/2023 due to an increase in the total return index and solvency index. Debt to equity declined from 0.09 to 0.08, and the quick ratio increased from 2.7 to 2.73.
C
Hold
11/10/2022Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 11/10/2022 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 39.17% from $226.2M to $137.6M, earnings per share declined from $2.48 to $1.59, and total revenue declined 10.94% from $771.3M to $686.9M.
West Pharmaceutical Services, Inc. (WST) was downgraded to C from C+ on 11/10/2022 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 39.17% from $226.2M to $137.6M, earnings per share declined from $2.48 to $1.59, and total revenue declined 10.94% from $771.3M to $686.9M.
C
Hold
7/11/2022Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 7/11/2022 due to a decline in the volatility index, total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 7/11/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy
6/2/2022Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 6/2/2022 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.11 to 1.99.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 6/2/2022 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.11 to 1.99.
B
Buy
1/10/2022Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 1/10/2022 due to a decline in the total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 1/10/2022 due to a decline in the total return index.
B
Buy
12/20/2021Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 12/20/2021 due to an increase in the total return index, volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 12/20/2021 due to an increase in the total return index, volatility index and valuation index.
B
Buy
12/3/2021Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 12/3/2021 due to a decline in the total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 12/3/2021 due to a decline in the total return index and valuation index.
B
Buy
11/18/2021Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 11/18/2021 due to an increase in the total return index, volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 11/18/2021 due to an increase in the total return index, volatility index and valuation index.
B
Buy
11/3/2021Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 11/3/2021 due to a decline in the growth index and total return index. EBIT declined 12.6% from $208.8M to $182.5M, earnings per share declined from $2.47 to $2.31, and total revenue declined 2.36% from $723.6M to $706.5M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 11/3/2021 due to a decline in the growth index and total return index. EBIT declined 12.6% from $208.8M to $182.5M, earnings per share declined from $2.47 to $2.31, and total revenue declined 2.36% from $723.6M to $706.5M.
B
Buy
7/30/2021Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 7/30/2021 due to a major increase in the total return index, valuation index and growth index. Operating cash flow increased 62.8% from $88.7M to $144.4M, earnings per share increased from $1.99 to $2.47, and EBIT increased 18.56% from $178.3M to $211.4M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 7/30/2021 due to a major increase in the total return index, valuation index and growth index. Operating cash flow increased 62.8% from $88.7M to $144.4M, earnings per share increased from $1.99 to $2.47, and EBIT increased 18.56% from $178.3M to $211.4M.
B
Buy
2/4/2021Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/4/2021 due to an increase in the total return index, volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/4/2021 due to an increase in the total return index, volatility index and valuation index.
B
Buy
1/20/2021Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 1/20/2021 due to a large decline in the total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 1/20/2021 due to a large decline in the total return index and valuation index.
B
Buy
1/4/2021Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 1/4/2021 due to a major increase in the total return index and volatility index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 1/4/2021 due to a major increase in the total return index and volatility index.
B
Buy
12/18/2020Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/18/2020 due to a decline in the volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/18/2020 due to a decline in the volatility index and valuation index.
B
Buy
2/4/2020Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/4/2020 due to an increase in the volatility index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/4/2020 due to an increase in the volatility index.
B
Buy
12/23/2019Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/23/2019 due to a decline in the valuation index, growth index and efficiency index. Net income declined 14.83% from $66.1M to $56.3M, earnings per share declined from $0.88 to $0.75, and EBIT declined 4.76% from $77.7M to $74M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/23/2019 due to a decline in the valuation index, growth index and efficiency index. Net income declined 14.83% from $66.1M to $56.3M, earnings per share declined from $0.88 to $0.75, and EBIT declined 4.76% from $77.7M to $74M.
B
Buy
5/31/2019Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 5/31/2019 due to a noticeable increase in the total return index, growth index and efficiency index. EBIT increased 8.93% from $62.7M to $68.3M, net income increased 6.54% from $52M to $55.4M, and earnings per share increased from $0.6891 to $0.73.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 5/31/2019 due to a noticeable increase in the total return index, growth index and efficiency index. EBIT increased 8.93% from $62.7M to $68.3M, net income increased 6.54% from $52M to $55.4M, and earnings per share increased from $0.6891 to $0.73.
B
Buy
3/4/2019Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 3/4/2019 due to a decline in the growth index, valuation index and volatility index. Operating cash flow declined 17.19% from $88.4M to $73.2M, earnings per share declined from $0.73 to $0.6891, and EBIT declined 3.69% from $65.1M to $62.7M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 3/4/2019 due to a decline in the growth index, valuation index and volatility index. Operating cash flow declined 17.19% from $88.4M to $73.2M, earnings per share declined from $0.73 to $0.6891, and EBIT declined 3.69% from $65.1M to $62.7M.
B
Buy
2/15/2019Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/15/2019 due to an increase in the volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 2/15/2019 due to an increase in the volatility index and valuation index.
B
Buy
1/25/2019Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 1/25/2019 due to a decline in the total return index, growth index and volatility index. Total revenue declined 3.53% from $447.5M to $431.7M, and earnings per share declined from $0.75 to $0.73.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 1/25/2019 due to a decline in the total return index, growth index and volatility index. Total revenue declined 3.53% from $447.5M to $431.7M, and earnings per share declined from $0.75 to $0.73.
B
Buy
8/2/2018Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 8/2/2018 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 82.22% from $45M to $82M, earnings per share increased from $0.58 to $0.75, and EBIT increased 10.18% from $57M to $62.8M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 8/2/2018 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 82.22% from $45M to $82M, earnings per share increased from $0.58 to $0.75, and EBIT increased 10.18% from $57M to $62.8M.
B
Buy
5/11/2018Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 5/11/2018 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 44.79% from $81.5M to $45M, earnings per share declined from $0.67 to $0.58, and EBIT declined 6.53% from $59.7M to $55.8M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 5/11/2018 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 44.79% from $81.5M to $45M, earnings per share declined from $0.67 to $0.58, and EBIT declined 6.53% from $59.7M to $55.8M.
B
Buy
1/29/2018Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 1/29/2018 due to a decline in the valuation index, volatility index and total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 1/29/2018 due to a decline in the valuation index, volatility index and total return index.
B
Buy
12/21/2017Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 12/21/2017 due to a major increase in the total return index, growth index and efficiency index. Net income increased 31.44% from $38.8M to $51M, earnings per share increased from $0.51 to $0.67, and EBIT increased 17.53% from $54.2M to $63.7M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 12/21/2017 due to a major increase in the total return index, growth index and efficiency index. Net income increased 31.44% from $38.8M to $51M, earnings per share increased from $0.51 to $0.67, and EBIT increased 17.53% from $54.2M to $63.7M.
B
Buy
9/6/2017Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 9/6/2017 due to a noticeable decline in the total return index, volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 9/6/2017 due to a noticeable decline in the total return index, volatility index and valuation index.
B
Buy
8/22/2017Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 8/22/2017 due to an increase in the valuation index, volatility index and dividend index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 8/22/2017 due to an increase in the valuation index, volatility index and dividend index.
B
Buy
8/7/2017Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 8/7/2017 due to a large decline in the total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 8/7/2017 due to a large decline in the total return index.
B
Buy
8/3/2017Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 8/3/2017 due to a noticeable decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.81 to $0.51, net income declined 36.29% from $60.9M to $38.8M, and EBIT declined 12.01% from $61.6M to $54.2M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 8/3/2017 due to a noticeable decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.81 to $0.51, net income declined 36.29% from $60.9M to $38.8M, and EBIT declined 12.01% from $61.6M to $54.2M.
A
Buy
6/29/2017Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 6/29/2017 due to a large increase in the total return index, volatility index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 6/29/2017 due to a large increase in the total return index, volatility index and valuation index.
B
Buy
6/12/2017Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 6/12/2017 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from $0.5163 to $0.81, EBIT increased 10% from $56M to $61.6M, and total revenue increased 1.41% from $382.3M to $387.7M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 6/12/2017 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from $0.5163 to $0.81, EBIT increased 10% from $56M to $61.6M, and total revenue increased 1.41% from $382.3M to $387.7M.
B
Buy
12/29/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 12/29/2016 due to an increase in the total return index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 12/29/2016 due to an increase in the total return index.
B
Buy
12/12/2016Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/12/2016 due to a decline in the valuation index, volatility index and dividend index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 12/12/2016 due to a decline in the valuation index, volatility index and dividend index.
B
Buy
11/2/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 11/2/2016 due to a major increase in the valuation index, efficiency index and growth index. Total capital increased 2.41% from $1.34B to $1.37B.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 11/2/2016 due to a major increase in the valuation index, efficiency index and growth index. Total capital increased 2.41% from $1.34B to $1.37B.
B
Buy
10/11/2016Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 10/11/2016 due to a significant decline in the total return index and volatility index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 10/11/2016 due to a significant decline in the total return index and volatility index.
B
Buy
9/26/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 9/26/2016 due to an increase in the total return index, solvency index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 9/26/2016 due to an increase in the total return index, solvency index and valuation index.
B
Buy
8/3/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 8/3/2016 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 2,440% from $3M to $76.2M, earnings per share increased from $0.3 to $0.6, and EBIT increased 10.04% from $55.8M to $61.4M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 8/3/2016 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 2,440% from $3M to $76.2M, earnings per share increased from $0.3 to $0.6, and EBIT increased 10.04% from $55.8M to $61.4M.
C
Hold
5/9/2016Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 5/9/2016 due to a substantial decline in the growth index, valuation index and efficiency index. Operating cash flow declined 95.59% from $68M to $3M, net income declined 33.83% from $33.4M to $22.1M, and earnings per share declined from $0.4505 to $0.3.
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 5/9/2016 due to a substantial decline in the growth index, valuation index and efficiency index. Operating cash flow declined 95.59% from $68M to $3M, net income declined 33.83% from $33.4M to $22.1M, and earnings per share declined from $0.4505 to $0.3.
B
Buy
4/29/2016Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 4/29/2016 due to a decline in the total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B- from B on 4/29/2016 due to a decline in the total return index and valuation index.
B
Buy
4/14/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 4/14/2016 due to a substantial increase in the total return index and solvency index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B from B- on 4/14/2016 due to a substantial increase in the total return index and solvency index.
B
Buy
3/2/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 3/2/2016 due to a substantial increase in the growth index, total return index and efficiency index. Earnings per share increased from $0.02 to $0.4505, net income increased 2,126.67% from $1.5M to $33.4M, and total revenue increased 4.41% from $344.5M to $359.7M.
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 3/2/2016 due to a substantial increase in the growth index, total return index and efficiency index. Earnings per share increased from $0.02 to $0.4505, net income increased 2,126.67% from $1.5M to $33.4M, and total revenue increased 4.41% from $344.5M to $359.7M.
C
Hold
2/25/2016Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 2/25/2016 due to a decline in the total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B- on 2/25/2016 due to a decline in the total return index.
B
Buy
1/6/2016Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 1/6/2016 due to a noticeable increase in the total return index and volatility index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B- from C+ on 1/6/2016 due to a noticeable increase in the total return index and volatility index.
C
Hold
11/4/2015Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B on 11/4/2015 due to a significant decline in the growth index, valuation index and total return index. EBIT declined 107.65% from $39.2M to -$3M, earnings per share declined from $0.38 to $0.02, and operating cash flow declined 11.23% from $77.5M to $68.8M.
West Pharmaceutical Services, Inc. (WST) was downgraded to C+ from B on 11/4/2015 due to a significant decline in the growth index, valuation index and total return index. EBIT declined 107.65% from $39.2M to -$3M, earnings per share declined from $0.38 to $0.02, and operating cash flow declined 11.23% from $77.5M to $68.8M.
B
Buy
10/16/2015Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 10/16/2015 due to a noticeable decline in the total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 10/16/2015 due to a noticeable decline in the total return index.
B
Buy
9/1/2015Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 9/1/2015 due to a noticeable decline in the total return index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 9/1/2015 due to a noticeable decline in the total return index.
A
Buy
8/17/2015Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 8/17/2015 due to an increase in the growth index, total return index and solvency index. The quick ratio increased from 1.34 to 1.44, total revenue increased 7.09% from $335.9M to $359.7M, and debt to equity declined from 0.35 to 0.33.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 8/17/2015 due to an increase in the growth index, total return index and solvency index. The quick ratio increased from 1.34 to 1.44, total revenue increased 7.09% from $335.9M to $359.7M, and debt to equity declined from 0.35 to 0.33.
B
Buy
8/4/2015Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 8/4/2015 due to an increase in the total return index and valuation index.
West Pharmaceutical Services, Inc. (WST) was upgraded to B+ from B on 8/4/2015 due to an increase in the total return index and valuation index.
B
Buy
7/20/2015Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 7/20/2015 due to a noticeable decline in the growth index, volatility index and valuation index. Operating cash flow declined 104.13% from $46M to -$1.9M, and total revenue declined 3.97% from $349.8M to $335.9M.
West Pharmaceutical Services, Inc. (WST) was downgraded to B from B+ on 7/20/2015 due to a noticeable decline in the growth index, volatility index and valuation index. Operating cash flow declined 104.13% from $46M to -$1.9M, and total revenue declined 3.97% from $349.8M to $335.9M.
B
Buy
5/4/2015Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 5/4/2015 due to a decline in the total return index and volatility index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 5/4/2015 due to a decline in the total return index and volatility index.
A
Buy
4/17/2015Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 4/17/2015 due to a large increase in the total return index, volatility index and solvency index.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 4/17/2015 due to a large increase in the total return index, volatility index and solvency index.
B
Buy
11/5/2014Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 11/5/2014 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 20.95% from $54.9M to $43.4M, earnings per share declined from $0.52 to $0.43, and the quick ratio declined from 2.01 to 1.83.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 11/5/2014 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 20.95% from $54.9M to $43.4M, earnings per share declined from $0.52 to $0.43, and the quick ratio declined from 2.01 to 1.83.
A
Buy
10/16/2014Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 10/16/2014 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 629.55% from $8.8M to $64.2M, EBIT increased 38.64% from $39.6M to $54.9M, and earnings per share increased from $0.38 to $0.52.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 10/16/2014 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 629.55% from $8.8M to $64.2M, EBIT increased 38.64% from $39.6M to $54.9M, and earnings per share increased from $0.38 to $0.52.
B
Buy
7/17/2014Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 7/17/2014 due to a decline in the volatility index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 7/17/2014 due to a decline in the volatility index.
A
Buy
5/27/2014Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 5/27/2014 due to an increase in the volatility index, valuation index and solvency index.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 5/27/2014 due to an increase in the volatility index, valuation index and solvency index.
B
Buy
5/9/2014Downgrade
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 5/9/2014 due to a decline in the efficiency index.
West Pharmaceutical Services, Inc. (WST) was downgraded to B+ from A- on 5/9/2014 due to a decline in the efficiency index.
A
Buy
3/20/2014Upgraded
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 3/20/2014 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 29.08% from $53.3M to $68.8M, debt to equity declined from 0.49 to 0.42, and the quick ratio increased from 1.73 to 1.79.
West Pharmaceutical Services, Inc. (WST) was upgraded to A- from B+ on 3/20/2014 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 29.08% from $53.3M to $68.8M, debt to equity declined from 0.49 to 0.42, and the quick ratio increased from 1.73 to 1.79.
NYSE
01/10/2025 4:00PM Eastern
Quotes delayed
